STOK Stock: Price, Earnings History and SEC Filings
Stoke Therapeutics, Inc. (STOK) last traded at $26.29, down 0.23% on the latest session and up 1.1% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-1.08 against an analyst estimate of $-0.88, a miss of 22.7%.
$26.29 -0.23%
1 month+1.12%
52-week high$40.22
52-week low$20.32
Volume1.86M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
STOK earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $-1.08 | $-0.88 | -22.73% |
| Jun 2026 | Aug 3, 2026 | $-0.93 | $-0.82 | -13.41% |
| Mar 2026 | May 7, 2026 | $-0.79 | $-0.80 | +1.25% |
| Dec 2025 | Mar 16, 2026 | $-0.97 | $-0.75 | -29.33% |
STOK beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for STOK
SEC filing data is not available right now. You can search for STOK on SEC EDGAR.
STOK news
- Stoke Therapeutics (STOK) Stock Price Faces Q3 Results Cash Burn QuestionOct 31, 2026 · finance.yahoo.com
- Stoke (STOK) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- Stoke Therapeutics, Inc. Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
- Stoke Therapeutics Q3 Earnings Call HighlightsOct 30, 2026 · marketbeat.com
- Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesOct 29, 2026 · finance.yahoo.com
- Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsightOct 27, 2026 · finance.yahoo.com
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial UpdatesOct 22, 2026 · finance.yahoo.com
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. (STOK) is a US-listed public company on Nasdaq.